RBC's Bullish Neurologist Survey Leads To A $108 Price Target On Sarepta Therapeutics

A recent neurologist survey and the latest call with DMD KOLs support a bullish stance on the commercial prospects of Sarepta Therapeutics Inc’s SRPT EXONDYS 51.

RBC Capital Markets’ Simos Simeonidis maintained an Outperform rating, while raising the price target from $83 to $108.

The DMD KOLs were more bullish than the results from the survey of 100 neurologists, and suggested wide use of the EXONDYS 51, Simeonidis mentioned. He adjusted the revenue model for EXONDYS 51 to reflect higher penetration rates and earlier peak sales.

Related Link: Dr. Ron Farkas Leaves The FDA, Boosting Sarepta Shares: Here's Where You Could've Heard The News First

More Bullish Than Earlier

Simeonidis believes the launch will be a very successful one, “once the logistics of reimbursement are slowly ironed out for patients in the first 2-3 quarters.”

As suggested by the KOLs, reimbursement is unlikely to become a significant issue, given the product’s broad label, apparent safety and the urgency of DMD patients to gain immediate access to this agent.

“We have made similar adjustments to our projections in the revenue models for Sarepta’s follow-on agents under development, which we have probability-adjusted based on their stage of development (33%-50%),” the analyst wrote.

Simeonidis added that although the price target was ~$50 higher than Sarepta’s current share price, it incorporated conservative assumptions.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!